Northwire Canada EditionMonday, July 13, 2026
Northwire
OMI 0.315 +0.0% BMM 3.80 +0.0% CGD 0.630 +10.5% OCG 0.275 −1.8% CAMB 0.980 −2.0% HMR 0.610 −1.6% GOFL 0.025 +0.0% SIG 1.02 −1.0% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.400 +0.0% LIB 0.800 −12.1% SMY 0.290 +23.4% SAG 1.02 +0.0% OMI 0.315 +0.0% BMM 3.80 +0.0% CGD 0.630 +10.5% OCG 0.275 −1.8% CAMB 0.980 −2.0% HMR 0.610 −1.6% GOFL 0.025 +0.0% SIG 1.02 −1.0% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.400 +0.0% LIB 0.800 −12.1% SMY 0.290 +23.4% SAG 1.02 +0.0%
Production / Operations

Else Nutrition Achieves Transformative Operational and Financial Progress in 2025

BABY · Price

Executive Summary

  • Else Nutrition reported a comprehensive transformation in 2025 that reduced headcount, cut operating costs, and streamlined supply‑chain and manufacturing processes.
  • The company highlighted an FDA regulatory development that “streamlines approval pathways for plant‑based infant formulas,” creating a clearer path to product approvals.
  • Management projects cash‑flow breakeven between late 2026 and early 2027 as the business leverages lower costs, stabilized inventory, and growing demand for its plant‑based infant nutrition portfolio.

Key Details

  • Operational Restructuring: Company‑wide initiative in 2025 reshaped operating structure, resulting in a leaner organization with reduced headcount and lower operating expenses.
  • Supply‑Chain & Manufacturing Improvements: Optimized supply chain, increased manufacturing efficiency, and prioritized high‑impact marketing spend on core product categories (plant‑based toddler and baby cereals).
  • Revenue Impact 2025: Temporary production funding shortfalls caused supply constraints and revenue losses; however, the firm expects a more stable inventory in 2026 to support growth.
  • Regulatory Milestone: In November 2025, the U.S. FDA was directed (via a presidentially signed funding package) to streamline approval pathways for non‑dairy, non‑soy plant‑based infant formulas, providing Else Nutrition with a clearer regulatory route.
  • Strategic Partnerships: Early‑stage discussions underway with global nutrition and food companies regarding distribution, co‑manufacturing, and research collaborations.
  • Cash‑Flow Outlook: Management targets cash‑flow breakeven between late 2026 and early 2027, driven by cost reductions, improved margins, and anticipated revenue growth.
  • CEO Quote: “We emerged from 2025 more focused, disciplined, and aligned with long‑term opportunities… confident in our ability to achieve sustainable growth, advance our innovation pipeline, and move toward cash‑flow breakeven.” – Hamutal Yitzhak, CEO & Co‑Founder.

Notable Quotes

  • “We took decisive actions to strengthen our operations, streamline our cost structure, and reinforce the foundation of our business… we are energized by the momentum we have created and confident in our ability to achieve sustainable growth.” – Hamutal Yitzhak, CEO & Co‑Founder.
Read the original news release →

More from ELSE NUTRITION HOLDINGS INC. J